84 related articles for article (PubMed ID: 22445689)
1. A single amino acid substitution controls DAF-dependent phenotype of echovirus 11 in rhabdomyosarcoma cells.
Novoselov AV; Rezaykin AV; Sergeev AG; Fadeyev FA; Grigoryeva JV; Sokolova ZI
Virus Res; 2012 Jun; 166(1-2):87-96. PubMed ID: 22445689
[TBL] [Abstract][Full Text] [Related]
2. Two clusters of mutations map distinct receptor-binding sites of echovirus 11 for the decay-accelerating factor (CD55) and for canyon-binding receptors.
Rezaikin AV; Novoselov AV; Sergeev AG; Fadeyev FA; Lebedev SV
Virus Res; 2009 Oct; 145(1):74-9. PubMed ID: 19540285
[TBL] [Abstract][Full Text] [Related]
3. Role of class I human leukocyte antigen molecules in early steps of echovirus infection of rhabdomyosarcoma cells.
Chevaliez S; Balanant J; Maillard P; Lone YC; Lemonnier FA; Delpeyroux F
Virology; 2008 Nov; 381(2):203-14. PubMed ID: 18823925
[TBL] [Abstract][Full Text] [Related]
4. Cytolytic replication of coxsackievirus B2 in CAR-deficient rhabdomyosarcoma cells.
Polacek C; Ekström JO; Lundgren A; Lindberg AM
Virus Res; 2005 Nov; 113(2):107-15. PubMed ID: 15964091
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.
Johansson ES; Xing L; Cheng RH; Shafren DR
J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647
[TBL] [Abstract][Full Text] [Related]
6. Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.
Pan J; Zhang L; Organtini LJ; Hafenstein S; Bergelson JM
J Virol; 2015 Jan; 89(2):1324-8. PubMed ID: 25392210
[TBL] [Abstract][Full Text] [Related]
7. Echovirus infection of rhabdomyosarcoma cells is inhibited by antiserum to the complement control protein CD59.
Goodfellow IG; Powell RM; Ward T; Spiller OB; Almond JW; Evans DJ
J Gen Virol; 2000 May; 81(Pt 5):1393-401. PubMed ID: 10769083
[TBL] [Abstract][Full Text] [Related]
8. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor.
Martino TA; Petric M; Brown M; Aitken K; Gauntt CJ; Richardson CD; Chow LH; Liu PP
Virology; 1998 May; 244(2):302-14. PubMed ID: 9601501
[TBL] [Abstract][Full Text] [Related]
9. Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.
Schmidtke M; Selinka HC; Heim A; Jahn B; Tonew M; Kandolf R; Stelzner A; Zell R
Virology; 2000 Sep; 275(1):77-88. PubMed ID: 11017789
[TBL] [Abstract][Full Text] [Related]
10. Characterization of echoviruses that bind decay accelerating factor (CD55): evidence that some haemagglutinating strains use more than one cellular receptor.
Powell RM; Schmitt V; Ward T; Goodfellow I; Evans DJ; Almond JW
J Gen Virol; 1998 Jul; 79 ( Pt 7)():1707-13. PubMed ID: 9680134
[TBL] [Abstract][Full Text] [Related]
11. Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF.
Spiller OB; Goodfellow IG; Evans DJ; Almond JW; Morgan BP
J Infect Dis; 2000 Jan; 181(1):340-3. PubMed ID: 10608785
[TBL] [Abstract][Full Text] [Related]
12. Development of a recombinant CHO cell model for the investigation of CAR and DAF role during early steps of echovirus 6 infection.
Renois F; Hong SS; Le Naour R; Gafa V; Talmud D; Andréoletti L; Lévêque N
Virus Res; 2011 Jun; 158(1-2):46-54. PubMed ID: 21420451
[TBL] [Abstract][Full Text] [Related]
13. Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity.
Shafren DR; Dorahy DJ; Thorne RF; Kinoshita T; Barry RD; Burns GF
J Immunol; 1998 Mar; 160(5):2318-23. PubMed ID: 9498772
[TBL] [Abstract][Full Text] [Related]
14. Decay-accelerating factor binding determines the entry route of echovirus 11 in polarized epithelial cells.
Sobo K; Rubbia-Brandt L; Brown TD; Stuart AD; McKee TA
J Virol; 2011 Dec; 85(23):12376-86. PubMed ID: 21917947
[TBL] [Abstract][Full Text] [Related]
15. Determination of the structure of a decay accelerating factor-binding clinical isolate of echovirus 11 allows mapping of mutants with altered receptor requirements for infection.
Stuart AD; McKee TA; Williams PA; Harley C; Shen S; Stuart DI; Brown TD; Lea SM
J Virol; 2002 Aug; 76(15):7694-704. PubMed ID: 12097583
[TBL] [Abstract][Full Text] [Related]
16. [Mapping of point mutations leading to loss of virus ECH011 affinity for receptor DAF (CD55)].
Rezaĭkin AB; Novoselov AB; Fadeev FA; Sergeev AG; Lebedev SB
Vopr Virusol; 2009; 54(1):41-4. PubMed ID: 19253731
[TBL] [Abstract][Full Text] [Related]
17. Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.
Carson SD; Chapman NM; Hafenstein S; Tracy S
J Virol; 2011 Apr; 85(7):3306-14. PubMed ID: 21270163
[TBL] [Abstract][Full Text] [Related]
18. Structural and functional insights into the interaction of echoviruses and decay-accelerating factor.
Pettigrew DM; Williams DT; Kerrigan D; Evans DJ; Lea SM; Bhella D
J Biol Chem; 2006 Feb; 281(8):5169-77. PubMed ID: 16272562
[TBL] [Abstract][Full Text] [Related]
19. Interaction of decay-accelerating factor with coxsackievirus B3.
Hafenstein S; Bowman VD; Chipman PR; Bator Kelly CM; Lin F; Medof ME; Rossmann MG
J Virol; 2007 Dec; 81(23):12927-35. PubMed ID: 17804498
[TBL] [Abstract][Full Text] [Related]
20. Enterovirus 70 receptor utilization is controlled by capsid residues that also regulate host range and cytopathogenicity.
Kim MS; Racaniello VR
J Virol; 2007 Aug; 81(16):8648-55. PubMed ID: 17537857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
